CTOs on the Move


 
SynGen advances regenerative medicine and other emerging applications for high-value cells by providing researchers, clinicians and manufacturers with innovative, robust systems that improve the recovery, purity and viability of stem and other clinically important cells from umbilical cord blood, peripheral blood, bone marrow, and cell culture.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.syngeninc.com
  • 2125 19th St Suite 120
    Sacramento, CA USA 95818
  • Phone: 916.706.0923

Executives

Name Title Contact Details

Similar Companies

ACT Center of Indiana

ACT Center of Indiana is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Visit Columbus GA

Looking for things to do in Georgia? Find attractions, events and more in Columbus, GA. Ride the longest urban whitewater rafting course in the world. Learn more.

Hunt Memorial Hospital District

March 6, 2006 - As the Hunt Memorial Hospital District continues to develop the final plans for the new Cancer Center, Presbyterian Hospital of Greenville is keeping sight of the softer side of patient care.

Redwood Green Corporation

Redwood Green Corp. delivers high-quality, safe, sustainable, innovative and accessible cannabis-derived products that support individual well-being. Safety and high quality is a critical commitment from Redwood Green, both for our own brands as well as the partners with whom we do business. The drive behind what we do is rooted in improving well-being and quality of life for a wide range of audiences, ensuring we grow and improve upon what is currently available for consumers in the cannabinoids market. The company is publicly traded and listed on the OTC as RDGC.

Cellanyx

Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.